These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19762694)

  • 1. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register.
    Toyoda K; Koga M; Naganuma M; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Okada Y; Hasegawa Y; Kario K; Okuda S; Nishiyama K; Minematsu K;
    Stroke; 2009 Nov; 40(11):3591-5. PubMed ID: 19762694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
    Albers GW; Bates VE; Clark WM; Bell R; Verro P; Hamilton SA
    JAMA; 2000 Mar; 283(9):1145-50. PubMed ID: 10703776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous alteplase at 0.6 mg/kg for acute stroke patients with basilar artery occlusion: the stroke acute management with urgent risk factor assessment and improvement (SAMURAI) Recombinant tissue plasminogen activator registry.
    Miyagi T; Koga M; Shiokawa Y; Nakagawara J; Hasegawa Y; Furui E; Kimura K; Kario K; Okuda S; Yamagami H; Okada Y; Nezu T; Maeda K; Endo K; Minematsu K; Toyoda K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1098-106. PubMed ID: 23063059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
    Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early ischemic change on CT versus diffusion-weighted imaging for patients with stroke receiving intravenous recombinant tissue-type plasminogen activator therapy: stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry.
    Nezu T; Koga M; Nakagawara J; Shiokawa Y; Yamagami H; Furui E; Kimura K; Hasegawa Y; Okada Y; Okuda S; Kario K; Naganuma M; Maeda K; Minematsu K; Toyoda K
    Stroke; 2011 Aug; 42(8):2196-200. PubMed ID: 21719764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry.
    Nezu T; Koga M; Kimura K; Shiokawa Y; Nakagawara J; Furui E; Yamagami H; Okada Y; Hasegawa Y; Kario K; Okuda S; Nishiyama K; Naganuma M; Minematsu K; Toyoda K
    Neurology; 2010 Aug; 75(6):555-61. PubMed ID: 20697108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke.
    Nakashima T; Toyoda K; Koga M; Matsuoka H; Nagatsuka K; Takada T; Naritomi H; Minematsu K
    Int J Stroke; 2009 Dec; 4(6):425-31. PubMed ID: 19930051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke outcomes of Japanese patients with major cerebral artery occlusion in the post-alteplase, pre-MERCI era.
    Endo K; Koga M; Sakai N; Yamagami H; Furui E; Matsumoto Y; Shiokawa Y; Yoshimura S; Okada Y; Nakagawara J; Hyogo T; Hasegawa Y; Nagashima H; Fujinaka T; Hyodo A; Terada T; Toyoda K;
    J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):805-10. PubMed ID: 22721823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012.
    Tong X; George MG; Yang Q; Gillespie C
    Int J Stroke; 2014 Aug; 9(6):728-34. PubMed ID: 24024962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcome of Patients With Large Vessel Occlusion and Low National Institutes of Health Stroke Scale Scores: Subanalysis of the RESCUE-Japan Registry 2.
    Saito T; Itabashi R; Yazawa Y; Uchida K; Yamagami H; Sakai N; Morimoto T; Yoshimura S;
    Stroke; 2020 May; 51(5):1458-1463. PubMed ID: 32295504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose intravenous recombinant tissue-type plasminogen activator therapy for patients with stroke outside European indications: Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rtPA Registry.
    Koga M; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Okada Y; Hasegawa Y; Kario K; Okuda S; Endo K; Miyagi T; Osaki M; Minematsu K; Toyoda K
    Stroke; 2012 Jan; 43(1):253-5. PubMed ID: 21960585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous thrombolysis for patients with reverse magnetic resonance angiography and diffusion-weighted imaging mismatch: SAMURAI and NCVC rt-PA Registries.
    Sakamoto Y; Koga M; Kimura K; Nagatsuka K; Okuda S; Kario K; Hasegawa Y; Okada Y; Yamagami H; Furui E; Nakagawara J; Shiokawa Y; Okata T; Kobayashi J; Tanaka E; Minematsu K; Toyoda K
    Eur J Neurol; 2014 Mar; 21(3):419-26. PubMed ID: 24261412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of mechanical thrombectomy following intravenous administration of recombinant tissue-type plasminogen activator for basilar artery occlusion.
    Deguchi I; Osada T; Kimura H; Hayashi T; Takahashi S; Takao M
    Clin Neurol Neurosurg; 2020 Jul; 194():105796. PubMed ID: 32247170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).
    Wahlgren N; Ahmed N; Eriksson N; Aichner F; Bluhmki E; Dávalos A; Erilä T; Ford GA; Grond M; Hacke W; Hennerici MG; Kaste M; Köhrmann M; Larrue V; Lees KR; Machnig T; Roine RO; Toni D; Vanhooren G;
    Stroke; 2008 Dec; 39(12):3316-22. PubMed ID: 18927461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
    Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI;
    Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials.
    Cucchiara B; Kasner SE; Tanne D; Levine SR; Demchuk A; Messe SR; Sansing L; Lees KR; Lyden P;
    Stroke; 2009 Sep; 40(9):3067-72. PubMed ID: 19608993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.